Citation

Charles D Mitchell, Miriam C. Chernoff, George R. Seage III, Murli R Purswani, Hans M.L. Spiegel, Gaston Zilleruelo, Carolyn Abibol, Barbara Heckman, Christopher B Ponce, James M Oleske. Predictors of Resolution and Persistence of Renal Laboratory Abnormalities in Pediatric HIV Infection. Pediatric Nephrology. 2014 Aug 24; 30(1):153-165. PMID: 25149850; PMCID: PMC4301405.

Citation

Qin M, Brummel S, Singh KK, Fenton T, Apector SA. Associations of Host Genetic Variants on CD4+ Lymphocyte Count and Plasma HIV-1 RNA in Antiretroviral Naïve Children. Pediaric Infectious Disease Journal. 2014 Sep 02; 33(9):946-952. PMID: 2797997; PMCID: PMC4216611.

Citation

R Kantor, D Bettendorf, RJ Bosch, M Mann, D Katzenstein, S Cu-Uvin, R D'Aquila, L Frenkel, S Fiscus, R Coombs, ACTG A5077 Study Team. HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-blood Compartments from HIV-1-Infected Men and Women Enrolled in AIDS Clinical Trials Group Study A5077. PLoS One. 2014 Apr 03; 9(4):e93537. PMID: 24699474; PMCID: PMC3974754.

Citation

A Garg, SA Spector. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. Journal of Infectious Diseases. 2014 Feb 01; 209(3):441-451. PMID: 23999600; PMCID: PMC3883171.

Citation

NH Tobin, GM Aldrovandi. Are infants unique in their ability to be "functionally cured" of HIV-1. Current HIV/AIDS Reports. 2014 Mar 20; 11(1):1-10. PMID: 24390641.

Citation

KB Larson, K Wang, C Delille, I Otofokun, EP Acosta. Pharmacokinetic Enhancers in HIV Therapeutics. Clinical Pharmacokinetics. 2014 Oct 20; 53(10):865-872. PMID: 25164142.

Citation

Sharon Nachman, Nan Zheng, Edward P Acosta, Hedy Teppler, Brenda Homony, Bobbie Graham, Terence Fenton, Xia Xu, Larissa Wenning, Stephen A Spector, Lisa M Frenkel, Carmelita Alvero, Carol Worrell, Edward Handelsman, Andrew Winzia, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team. Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1–Infected Children Aged 2 Through 18 Years. Clinical Infectious Diseases. 2014 Feb 15; 58(3):413-422. PMID: 24145879; PMCID: PMC3890333.

Citation

Jane C Lindsey, Michael D Hughes, Avy Violari, Susan H Eshleman, Elaine J Abrams, Mutsa Bwakura-Dangarembizi, Linda Barlow-Mosha, Portia Kamthunzi, Pauline M Sambo, Mark F Cotton, Harry Moultrie, Sandhya Khadse, Werner Schimana, Raziya Bobat, Bonnie Zimmer, Elizabeth Petzold, Lynne M Mofenson, Patrick Jean-Philippe, Paul Palumbo, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1060 Study Team. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediaric Infectious Disease Journal. 2014 Aug 15; 33(8):846-854. PMID: 25222305; PMCID: PMC4166566.

Citation

Dwight E Yin, Meredith G Warshaw, William C Miller, Hannah Castro, Susan A Fiscus, Lynda M Harper, Linda J Harrison, Nigel J Klein, Joanna Lewis, Ann J Melvin, Gareth Tudor-Williams, Ross E McKinney Jr, PENPACT-1 (PENTA 9/PACTG 390) Study Team. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. 2014 Oct 01; PMID: 25266426; PMCID: PMC4179097.

Citation

Discordant associations between SLCO1B1 521T¿C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. Therapeutic Drug Monitoring. 2013 Apr 01; 35(2):209-216. PMID: 23503447; PMCID: PMC3603284.